







Home ▶ All Journals ▶ Current Medical Research and Opinion ▶ List of Issues ▶ Volume 25, Issue 7 ▶ Projected economic impact of clinical fi ....

Current Medical Research and Opinion > Volume 25, 2009 - Issue 7

233 12

0

Views CrossRef citations to date Altmetric

Original Article

# Projected economic impact of clinical findings of generic entry of topiramate on G4 European countries

Pierre Emmanuel Paradis, Dominick Latrémouille-Viau, Yuliya Moore, Natalia Mishagina, Marie-Hélène Lafeuille, Patrick Lefebvre, ...show all

Pages 1793-1805 | Accepted 15 May 2009, Published online: 05 Jun 2009

**66** Cite this article **№** https://doi.org/10.1185/03007990903044374

Sample our
Bioscience
Journals
>> Sign in here to start your access to the latest two volumes for 14 days

Full Article

Figures & data

References

**66** Citations

Metrics

Reprints & Permissions

Read this article

We and our 848 partners store and/or access information on

a device, such as unique IDs in cookies to process personal data. You may accept or manage your choices by clicking

These choices will be signaled to our partners and will not

below, including your right to object where legitimate interest is used, or at any time in the privacy policy page.

# **ABSTRACT**

Objectiv

topiram

of Franc

impact of

† Top

We and our partners process data to provide:

affect browsing data. Privacy Policy

We Care About Your Privacy

Use precise geolocation data. Actively scan device characteristics for identification. Store and/or access information on a device. Personalised advertising and content, advertising and content measurement, audience research and services development.

List of Partners (vendors)

I Accept drug (AED)

ne settings

Essential Only
economic

Show Purpose

Isville, NJ,

sville, Nj,

ladie du re used. en-cohort

randed

Researcl Ouébec

Patients

design w

versus generic use of topiramate. Canadian healthcare utilization and costs (2007 CAN\$/person-year) were compared between periods using multivariate models. Annualized per-patient costs (2007€ or 2007£/person-year) were converted using Canadian utilization rates, European prices and service-use ratios. Non-parametric bootstrap served to assess statistical significance of cost differences. Topiramate market was forecasted following generic entry (09/2009–09/2010) using autoregressive models based on the European experience. The economic impact of generic topiramate entry was estimated for each country.

Results: A total of 1164 patients (mean age: 39.8 years, 61.7% female) were observed for 2.6 years on average. After covariates adjustment, generic-use periods were associated with increased pharmacy dispensings (other AEDs: +0.95/person-year, non-AEDs: +12.28/person-year, p < 0.001), hospitalizations ( + 0.08/person-year, p = 0.015), and lengths of hospital stays (+0.51 days/person-year, p < 0.001). Adjusted costs, excluding topiramate, were CAN\$1060/person-year higher during generic use (p = 0.005). Converted per-patient costs excluding topiramate were significantly higher for generic relative to brand periods in all European countries (adjusted cost differences per person-year: €706-815, p < 0.001 for all comparisons). System-wide costs would increase from 3.5 to 24.4% one year after generic entry.

Limitations: Study limitations include the absence of indirect costs, possible claim inaccuracies, and IMS data limitations.

Conclusions: Higher health costs were projected for G4 European countries from the

Canadian experience following the generic entry of toniramate

X

X

Trap

Declar:

This ana

Pharmac

Declar:

M.G. has disclosed that she is an employee of Janssen-Cilag EMEA. All other co-authors disclosed that they are employees of Analysis Group, Inc., which has received research grants to conduct this study from Janssen-Cilag EMEA.

All peer reviewers receive honoraria from CMRO for their review work. Peer reviewer 1 disclosed that he/she has received grant support from GlaxoSmithKline. Peer reviewer 2 disclosed that he/she has no relevant financial relationships.

# Acknowledgment


Janssen-Cilag EMEA participated in the design, review, and approval of the manuscript.

The authors disclosed no further assistance in preparation of this manuscript.

# Notes

† Topamax is a registered trade name of Ortho-McNeil Neurologics, Inc., Titusville, NJ, USA

\*Topamax is a registered trade name of Ortho-McNeil Neurologics, Inc., Titusville, NJ, USA



People also read

Recommended articles

Cited by 12

### Information for

**Authors** 

R&D professionals

Editors

Librarians

Societies

Opportunities

Reprints and e-prints

Advertising solutions

Accelerated publication

Corporate access solutions

## Open access

Overview

Open journals

Open Select

**Dove Medical Press** 

F1000Research

Help and information

Help and contact

Newsroom

All journals

Books

### Keep up to date

Register to receive personalised research and resources by email



Sign me up











Accessib



X

or & Francis Group